31 results about "Menstrual bleeding" patented technology

Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.

The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.

The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and / or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

The invention provides a traditional Chinese medicine preparation for treating gynecological uterine bleeding, which is a pure Chinese medicine preparation for treating women's uterine bleeding caused by yin deficiency and yang beat, cold evil in the cells, and continuous dripping. The preparation is mainly composed of lotus leaf , lotus, fried cypress leaves, leaking reed, Chuanxiong, soaked dried ginger, cattail, codonopsis, osmanthus, roasted rehmannia, angelica, white peony, mulberry, horsetail, herbal cream, random hair, gardenia, akebia It is made of 31 Chinese herbal medicines, such as roasted cat placenta, etc. On this basis, it is supplemented with decoctions or pills made of 25 Chinese herbal medicines, such as Tian AI, Chinese yam, Cimicifuga, Scutellaria baicalensis, Zhishouwu, Anemarrhena, etc. , the formula of the present invention is rigorous and scientific, and its course of treatment is short, quick to take effect, gentle in property of medicine, safe. The cure rate for menstrual blood dripping metrorrhagia is 96%, and the effective rate is 99%. The cure rate for menstrual blood metrorrhagia is 95%, and the effective rate is 97%. The cure rate for both types of metrorrhagia is It was 93%, and the effective rate was 95%.

The present invention relates to a drug for treating dysfunctional uterine bleeding, the India madder root, Sanguis Draconis and carbonized human hair are mixed and smashed into the fine powder, the Chinese angelica, baical skullcap root, trogopterus dung, cattail pollen, south dodder seed etc. are boiled by water and then filtered and condensed into the thick paste, the drug powder is added for even mixing, finally the product is prepared by smashing and filling in the capsule. The drug of the present invention has the effects of nourishing blood, cooling blood, activating blood circulation,removing blood stasis and hemostasis, which is applicable to the treatment of the advanced menstruation of women, large amount of menstrual bleeding or large amount of uterine bleeding caused by contraceptive ring embedding and drug abortion and other diseases; the present invention has the advantages of easy administration, accurate efficacy and no toxicity or side effects etc. The total effectiverate can reach 96.0 percent through the clinical efficacy observations of 100 cases of patients with dysfunctional uterine bleeding.

The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.